Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-30

Clinical Trial Update: Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study of selinexor (KPT-330) in advanced or metastatic solid tumors has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2021-04-30